Suppr超能文献

选择性 5-羟色胺再摄取抑制剂与白内障风险:一项巢式病例对照研究。

Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study.

机构信息

Center for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, Canada.

出版信息

Ophthalmology. 2010 Jun;117(6):1251-5. doi: 10.1016/j.ophtha.2009.11.042. Epub 2010 Mar 7.

Abstract

OBJECTIVE

Older-generation antidepressants have been associated with increasing the risk of cataracts. Although animal studies have alluded to a potential link between selective serotonin reuptake inhibitors (SSRIs) and the development of cataracts, no large population based-study has addressed this potential association. This study sought to quantify the risk of cataracts with SSRIs by conducting a pharmacoepidemiologic study using the linked administrative databases in the province of Quebec, Canada.

DESIGN

Nested case-control study.

PARTICIPANTS

A cohort of subjects who had received a coronary revascularization procedure from 1995 through 2004 in the province of Quebec, Canada.

METHODS

Using an administrative data set, a case-control study was conducted within a cohort of Quebec residents who had received a coronary revascularization procedure from 1995 through 2004. Cases were defined as those with the first diagnosis of a cataract diagnosed by an ophthalmologist. For each case, 10 controls were selected and matched to the cases by index date, age, and cohort entry. Crude and adjusted rate ratios (RRs) and corresponding confidence intervals (CIs) were computed for current use of SSRIs. Rate ratios were adjusted for gender, corticosteroid use, statins, high blood pressure, antihypertensives, and antidiabetics.

MAIN OUTCOME MEASURES

First International Classification for Disease (Ninth Revision) code for a cataract diagnosed by an ophthalmologist.

RESULTS

Eighteen thousand seven hundred eighty-four cases and 187 840 controls met our study inclusion criteria. The adjusted RR for cataracts among current users of SSRIs was 1.15 (95% CI, 1.08-1.23). The risk of cataracts was highest with fluvoxamine (RR, 1.39; 95% CI, 1.07-1.80), followed by venlafaxine (RR, 1.33; 95% CI, 1.14-1.55) and paroxetine for cataract surgery (RR, 1.23; 95% CI, 1.05-1.45). The average time to diagnosis of cataracts while on SSRI therapy was 656 days.

CONCLUSIONS

A possible association was found between current exposure to SSRIs, especially fluvoxamine and venlafaxine, and a future diagnosis of cataracts. The possibility that this observation may be the result of the effect of smoking, which could not be controlled for in the study, cannot be excluded. Future studies are needed to confirm this association in other populations.

摘要

目的

研究表明,老一代抗抑郁药会增加白内障的发病风险。虽然动物研究表明选择性 5-羟色胺再摄取抑制剂(SSRIs)与白内障的发生之间可能存在联系,但没有大型的基于人群的研究来证实这一潜在关联。本研究旨在通过对加拿大魁北克省的行政数据库进行药物流行病学研究,量化 SSRIs 类药物与白内障发生风险之间的关系。

设计

巢式病例对照研究。

参与者

该队列纳入了 1995 年至 2004 年间在加拿大魁北克省接受冠状动脉血运重建术的患者。

方法

利用行政数据集,在 1995 年至 2004 年间接受冠状动脉血运重建术的魁北克省居民队列中进行了一项病例对照研究。病例定义为首次被眼科医生诊断为白内障的患者。每例病例均匹配 10 名对照,按索引日期、年龄和队列纳入时间进行匹配。计算当前使用 SSRIs 类药物的病例与对照组的粗率比值(RR)和相应的置信区间(CI)。RR 调整了性别、皮质类固醇使用、他汀类药物、高血压、降压药和抗糖尿病药的影响。

主要观察指标

眼科医生诊断的白内障的国际疾病分类(第九版)代码。

结果

18784 例病例和 187840 例对照符合研究纳入标准。SSRIs 类药物当前使用者发生白内障的调整 RR 为 1.15(95%CI,1.08-1.23)。使用氟伏沙明(RR,1.39;95%CI,1.07-1.80)、文拉法辛(RR,1.33;95%CI,1.14-1.55)和帕罗西汀(RR,1.23;95%CI,1.05-1.45)治疗白内障手术的风险最高。在 SSRI 治疗期间诊断白内障的平均时间为 656 天。

结论

当前暴露于 SSRIs,尤其是氟伏沙明和文拉法辛,与未来诊断为白内障之间可能存在关联。不能排除这种观察结果可能是吸烟影响的结果,因为在研究中无法控制吸烟的影响。需要进一步的研究来证实这一关联在其他人群中的存在。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验